Roche Holding (RHHBF) (RHHBY) (RHHVF) said its experimental lung cancer drug divarasib extended patient survival by nearly six months compared with competing treatments in a late-stage clinical trial, potentially strengthening the Swiss pharmaceutical company’s oncology portfolio.

The treatment outperformed Amgen’s (